In accordance with Section 3 of the Articles of Association of Orion Corporation, 150,000 A-shares have been converted into 150,000 B-shares. The conversion has been entered into the Trade Register on 4 July 2014.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 41,372,816 A-shares and 99,885,012 B-shares.
| Olli Huotari |
SVP, Corporate Functions
| Jari Karlson |
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.